In summary, we revealed an overexpression of ECM components, which are associated with enhanced migratory capacities of tumour cells (TNC [76,77], FN1 [78]), resistance to chemotherapy (COL11A1 [43,75], SPP1 [79]) and adverse outcome (COL11A1 [42], TNC [80], FN1 [78]) in other primaries. This evidence concerns the gene COL11A1 and neoplasm.